01—Abstract
Summary
Summary of the 10-K filed February 27, 2008. Cited figures are marked; the original filing is the authoritative source.
Gilead Sciences, Inc. (GILD) reported robust growth in its 2007 annual filing, driven primarily by its HIV product portfolio, which represented 84%a of total product sales.
Truvada and the newly launched Atripla were key contributors, with total HIV product sales increasing by 48% year-over-year to $3.14 billionb. The company also saw significant growth in Hepsera and AmBisome. Royalty revenues increased by 12%, largely from Tamiflu sales, though the company anticipates a decline in these royalties in 2008 due to anticipated lower Tamiflu sales by Roche.
Looking ahead, Gilead is focused on expanding its international presence and advancing its pipeline, with new drug applications filed for Viread in Hepatitis B and aztreonam lysine for inhalation in cystic fibrosis. The company also highlighted its ongoing investment in research and development, which increased by 54%c in 2007, signaling a commitment to future growth through innovation and strategic acquisitions. Despite strong revenue growth, investors should note the potential impact of increased competition, regulatory scrutiny, and pricing pressures in the pharmaceutical market.
02—Key points
Key Highlights
- Total product sales reached $3.73 billion, a 44% increase year-over-year, primarily driven by strong performance in HIV products.
- HIV products generated $3.14 billion in sales, marking a 48% increase, with Truvada and Atripla being the main drivers.
- Atripla, a single-tablet HIV regimen, saw substantial sales growth of 339%, reflecting strong market uptake in the U.S. and expanding into European markets.
- Royalty revenues increased by 12% to $468.2 million, primarily from Tamiflu, though a decline is expected in 2008.
- The company filed new drug applications for Viread for Hepatitis B and aztreonam lysine for inhalation for cystic fibrosis, signaling pipeline progression.
- Research and Development expenses increased by 54% to $591.0 million, underscoring Gilead's commitment to innovation and pipeline development.
- Gilead expanded its international operations by establishing new subsidiaries and strengthened its manufacturing capabilities through acquisitions.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2007, Gilead Sciences, Inc. kept $0.37.
- Revenue$4.23B100.0%
- Cost of revenue−$768.8M18.2%
- Gross profit$3.46B81.8%
- Operating costs−$1.30B30.7%
- Operating income$2.16B51.2%
- Interest, other & tax−$579.6M13.7%
- Net income$1.58B37.5%
Where FY2007 revenue went
$4.23B- Net income: $1.58B, 37% of revenue
- Cost of revenue: $768.8M, 18% of revenue
- SG&A: $705.7M, 17% of revenue
- Other operating costs: $591.0M, 14% of revenue
- Interest, other & tax: $579.6M, 14% of revenue
Kept 37% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2007filed February 27, 2008Financial Statements
| Revenue | $4.23B |
| Cost of Revenue | $768.77M |
| Gross Profit | $3.46B |
| SG&A Expenses | $705.74M |
| Operating Expenses | $2.07B |
| Operating Income | $2.16B |
| Interest Expense | $63.18M |
| Net Income | $1.58B |
| EPS (Basic) | $0.85 |
| EPS (Diluted) | $0.82 |
| Shares Outstanding (Basic) | 1.86B |
| Shares Outstanding (Diluted) | 1.93B |
05—Questions
Frequently Asked Questions
What were the primary drivers of Gilead's revenue growth in 2007?
Gilead's revenue growth in 2007 was primarily driven by its HIV product portfolio, particularly Truvada and Atripla, which saw significant sales increases. The company also experienced growth in Hepsera and AmBisome sales, alongside an increase in royalty revenues.
What is Gilead's outlook regarding Tamiflu royalties?
Gilead expects a significant decline in royalty revenues from Tamiflu sales in 2008, as Roche, the marketer of Tamiflu, anticipates a marked decrease in sales related to pandemic planning efforts.
What key regulatory milestones did Gilead achieve or expect in 2007/2008?
In 2007, Gilead received U.S. FDA approval for Letairis for pulmonary arterial hypertension and filed supplemental NDAs for Viread for chronic hepatitis B and an NDA for aztreonam lysine for inhalation for cystic fibrosis. The company expected decisions from European and U.S. regulatory bodies on Viread for Hepatitis B in mid-2008.
How did Gilead's R&D spending change, and what does it indicate for the future?
Gilead's R&D expenses increased by 54% to $591.0 million in 2007, reflecting continued investment in internal discovery programs and collaborations. This significant increase signals a strong focus on advancing its pipeline and developing new therapeutics for future growth.
06—Continue